Department of Pathology, National Taiwan University Hospital Yunlin Branch, Yunlin 640, Taiwan.
Department of Biochemical Science and Technology, National Chiayi University, Chiayi 600, Taiwan.
Int J Mol Sci. 2024 Sep 9;25(17):9737. doi: 10.3390/ijms25179737.
Macrophages, pivotal components of the immune system, orchestrate host defense mechanisms in humans and mammals. Their polarization into classically activated macrophages (CAMs or M1) and alternatively activated macrophages (AAMs or M2) dictates distinct functional roles in immunity and tissue homeostasis. While the negative regulatory role of CD32b within the FC gamma receptor (FCγR) family is recognized across various immune cell types, its influence on macrophage polarization remains elusive. This study aimed to elucidate the regulatory role of CD32b in macrophage polarization and discern the differential expression markers between the M1 and M2 phenotypes following CD32b siRNA transfection. The results revealed a decrease in the CD32b levels in lipopolysaccharide (LPS)-treated M1 and an increase in interleukin-4 (IL-4)-treated M2 macrophages, as observed in macrophage Raw264.7 cells. Furthermore, CD32b siRNA transfection significantly downregulated the M2 markers (IL-10, VEGF, Arg-1, and STAT6), while upregulating the M1 markers (IL-6, NF-κB, NOS2, and STAT1) in the Raw264.7 cells. Similar findings were recapitulated in macrophage-rich adherent cells isolated from mouse spleens. Additionally, the cytopathological analysis of pleural effusions and ascitic fluids from patients with cancer revealed a positive correlation between advanced tumor stages, metastasis, and elevated CD32b levels. In conclusion, this study highlights the regulatory influence of CD32b in suppressing M1 expression and promoting M2 polarization. Moreover, heightened M2 activation and CD32b levels appear to correlate with tumor progression. A targeted CD32b blockade may serve as a novel therapeutic strategy to inhibit M2 macrophage polarization and is promising for anti-tumor intervention.
巨噬细胞是人体和哺乳动物免疫系统的关键组成部分,协调宿主防御机制。它们极化为经典激活的巨噬细胞(CAM 或 M1)和选择性激活的巨噬细胞(AAM 或 M2),在免疫和组织稳态中发挥不同的功能作用。虽然 CD32b 在 FCγ 受体(FCγR)家族中的负调控作用在各种免疫细胞类型中得到认可,但它对巨噬细胞极化的影响仍不清楚。本研究旨在阐明 CD32b 在巨噬细胞极化中的调节作用,并确定 CD32b siRNA 转染后 M1 和 M2 表型之间的差异表达标志物。结果显示,脂多糖(LPS)处理的 M1 中 CD32b 水平下降,白细胞介素 4(IL-4)处理的 M2 巨噬细胞中 CD32b 水平升高,在巨噬细胞 Raw264.7 细胞中观察到。此外,CD32b siRNA 转染显著下调了 M2 标志物(IL-10、VEGF、Arg-1 和 STAT6),而上调了 M1 标志物(IL-6、NF-κB、NOS2 和 STAT1)在 Raw264.7 细胞中。在从小鼠脾脏分离的富含巨噬细胞的贴壁细胞中也得到了类似的发现。此外,对来自癌症患者的胸腔积液和腹水的细胞病理学分析表明,高级肿瘤分期、转移和 CD32b 水平升高之间存在正相关。总之,本研究强调了 CD32b 在抑制 M1 表达和促进 M2 极化中的调节作用。此外,M2 激活和 CD32b 水平的升高似乎与肿瘤进展相关。靶向 CD32b 阻断可能成为抑制 M2 巨噬细胞极化的新治疗策略,并有望用于抗肿瘤干预。